异柠檬酸脱氢酶基因突变在软骨肉瘤中的 研究进展及展望

Isocitrate dehydrogenaseIDHis the more mutation-prone human metabolic gene. In the presence of nicotinamide adenine dinucleotide phosphateNADPHmutant IDH can bind to α-ketoglutaric acidα-KGand reduce it to 2-hydroxyglutaric acid2-HGparticipating in various biological processes of tumorigenesis. IDH has been widely studied in glioma and acute myeloid leukemiaand rarely in chondrosarcoma. Chondrosarcoma is prone to recurrence and metastasis due to the presence of high-frequency mutations in the IDH geneand treatment options are limited after recurrence or metastasis resulting in a poor prognosis for patients and an urgent clinical need to find new treatment options. This article reviews the role of IDH mutations in the developmentprognosisdifferential diagnosis and treatment of chondrosarcomafurther elaborates the biological role of IDH gene mutation in the occurrence and development of chondrosarcomaand provides an outlook on the development of powerful IDH inhibitors and anti-cancer drugsin order to provide a reference for the establishment of therapeutic regimen and prognostic evaluation.